| 1 | Office Memorandum regarding Clarification of Comprehensive permission for products imported for overprinting/stickering/stamping as per Rule 104A of Drugs and Cosmetics Rules 1945 | 2025-May-26 | | 438 KB |
| 2 | Inviting comments on Revised Guidelines on Similar Biologics- Regulatory requirements for Marketing Authorization in India, 2025 drafted by CDSCO | 2025-May-06 | | 1002 KB |
| 3 | Update on Information on Convalescent Plasma in COVID-19 | 2021-May-24 | | 33 KB |
| 4 | Office Memorandum regarding grant of permission for carrying out overprinting/stickering/stamping of imported drugs in certain cases under the provisions of Rule 104A | 2020-Jan-29 | | 540 KB |
| 5 | Revised List of Oxytocin Manufacturer | 2018-Jun-11 | | 425KB |
| 6 | Minutes of the meeting of 14th CBBDTEC | 2018-Jun-05 | | 2,853KB |
| 7 | Speical operation to prevent and detect illegal manufacturing of API formulations and Import of oxytocin in India | 2018-May-21 | | 671KB |
| 8 | Office Memorandum regarding speical operation to prevent and detect illegal manufacturing of API formulations and Import of oxytocin in India | 2018-May-21 | | 666KB |
| 9 | notification 19-2015-2020 | 2018-Feb-23 | | 422kb |
| 10 | Office Memorandum regarding Sampling of imported insuline formulations at port offices | 2018-Feb-07 | | 343KB |
| 11 | Notice regarding Online application for Human Vaccines on Sugam | 2017-Feb-06 | | 270KB |
| 12 | Office Memorandum: Avoiding multiple inspections of a facility using Risk Based Approach | 2016-Dec-20 | | 304KB |
| 13 | Office Memorandum: Issue of Clinical trial permission for r-DNA derived products Dated 20.12.2016 | 2016-Dec-20 | | 290KB |
| 14 | Circular: NOC for export of biological products (Vaccine & r-DNA products) under form 29 License to manufacture drugs for purposes of examination, test or analysis | 2016-Dec-13 | | 236KB |
| 15 | Office Memorandum: Timeline for CDL Kasauli to review and processing of applications referred for CMC or post appoval change | 2016-Dec-13 | | 269KB |
| 16 | Order: Timeline for communication of recommendation to the stakeholders based on the minutes of meeting of various Committees | 2016-Dec-13 | | 229KB |
| 17 | Office Memorandum: Form 29 license to manufacture drugs for examination, test or analysis for biological products ( Vaccine & r-DNA Products) | 2016-Dec-13 | | 476Kb |
| 18 | Presentation for Rabies Vaccine- regarding | 2016-Sep-08 | | 218KB |
| 19 | Notice dated 26.03.2016 regarding the proposed revised guidelines on Similar Biologics 2016 | 2016-Mar-26 | | 48KB |
| 20 | Notice dated 23.03.2016 regarding Preparation for global switch from tOPV to bOPV 2016 | 2016-Mar-23 | | 173KB |
| 21 | Notice | 2016-Mar-11 | | 108KB |
| 22 | Meeting of all Vaccine Manufacutres & Importers on 15th January 2015 | 2014-Dec-26 | | 513KB |
| 23 | Notice Regarding Approvals of Stem Cells and Cell Based Products Dated 18.02.2014 | 2014-Feb-18 | | 493KB |
| 24 | Notice dated 08.07.2013:- Revision of CDSCO Guidance for industry for biological products for applications under post approval changes PAC /1108 ver 1.1 | 2013-Jul-08 | | 508KB |
| 25 | Notice - clarification and requirements related to post approval changes as per CDSCO Guidance for industry for biological products | 2013-Jan-18 | | 603KB |